Ausgabe 2/2013
Inhalt (22 Artikel)
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes
Aleix Prat, Olga Karginova, Joel S. Parker, Cheng Fan, Xiaping He, Lisa Bixby, J. Chuck Harrell, Erick Roman, Barbara Adamo, Melissa Troester, Charles M. Perou
Genomic profiling of histological special types of breast cancer
Hugo M. Horlings, Britta Weigelt, Eric M. Anderson, Maryou B. Lambros, Alan Mackay, Rachael Natrajan, Charlotte K. Y. Ng, Felipe C. Geyer, Marc J. van de Vijver, Jorge S. Reis-Filho
Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling
Reginald M. Gorczynski, Zhiqi Chen, Ismat Khatri, Anna Podnos, Kai Yu
Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue
Myriam Vilasco, Laudine Communal, Justine Hugon-Rodin, Frédérique Penault-Llorca, Najat Mourra, Zherui Wu, Patricia Forgez, Anne Gompel
RAGE-binding S100A8/A9 promotes the migration and invasion of human breast cancer cells through actin polymerization and epithelial–mesenchymal transition
Chonggao Yin, Hongli Li, Baogang Zhang, Yuqing Liu, Guohua Lu, Shijun Lu, Lei Sun, Yueliang Qi, Xiaolong Li, Weiyi Chen
Expression and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 6 in breast cancers
Julia Y. S. Tsang, Ying Kin Kwok, Kit Wing Chan, Yun-Bi Ni, Wan Ning Vanessa Chow, Kwok Fai Lau, Mu-Min Shao, Siu Ki Chan, Puay-Hoon Tan, Gary M. Tse
The prognostic value of apoptotic and proliferative markers in breast cancer
Charla C. Engels, Francesca Ruberta, Esther M. de Kruijf, Gabi W. van Pelt, Vincent T. H. B. M. Smit, Gerrit Jan Liefers, Tomoko Matsushima, Masaki Shibayama, Hideki Ishihara, Cornelis J. H. van de Velde, Peter J. K. Kuppen
Upregulated WAVE3 expression is essential for TGF-β-mediated EMT and metastasis of triple-negative breast cancer cells
Molly A. Taylor, Gangarao Davuluri, Jenny G. Parvani, Barbara J. Schiemann, Michael K. Wendt, Edward F. Plow, William P. Schiemann, Khalid Sossey-Alaoui
Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients
Esther M. de Kruijf, Charla C. Engels, Willemien van de Water, Esther Bastiaannet, Vincent T. H. B. M. Smit, Cornelis J. H. van de Velde, Gerrit Jan Liefers, Peter J. K. Kuppen
Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns
Sabrina A. Bardowell, Joel Parker, Cheng Fan, Jamie Crandell, Charles M. Perou, Theresa Swift-Scanlan
Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients
John W. Smith II, Svetislava Vukelja, Amy Rabe, Nicole Wentworth-Hartung, Nicholas Koutrelakos, Spencer H. Shao, Thomas Whittaker, Yunfei Wang, Lina Asmar, Diane Opatt McDowell, Pralay Mukhopadhyay, Joyce O’Shaughnessy
A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk
Shaveta Vinayak, Erich J. Schwartz, Kristin Jensen, Jafi Lipson, Elizabeth Alli, Lisa McPherson, Adrian M. Fernandez, Vandana B. Sharma, Ashley Staton, Meredith A. Mills, Elizabeth A. Schackmann, Melinda L. Telli, Ani Kardashian, James M. Ford, Allison W. Kurian
Ultrasonic dissection system technology in breast cancer: a case–control study in a large cohort of patients requiring axillary dissection
F. Lumachi, S. M. M. Basso, D. A. Santeufemia, M. Bonamini, G. B. Chiara
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases
Nancy U. Lin, Rachel A. Freedman, Naren Ramakrishna, Jerry Younger, Anna Maria Storniolo, Jennifer R. Bellon, Steven E. Come, Rebecca S. Gelman, Gordon J. Harris, Mark A. Henderson, Shannon M. MacDonald, Anand Mahadevan, Emily Eisenberg, Jennifer A. Ligibel, Erica L. Mayer, Beverly Moy, April F. Eichler, Eric P. Winer
Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43
Kalliopi P. Siziopikou, Stewart J. Anderson, Melody A. Cobleigh, Thomas B. Julian, Douglas W. Arthur, Ping Zheng, Eleftherios P. Mamounas, Eduardo R. Pajon, Robert J. Behrens, Janice F. Eakle, Nick C. Leasure, James N. Atkins, Jonathan A. Polikoff, Thomas E. Seay, Worta J. McCaskill-Stevens, Rachel Rabinovitch, Joseph P. Costantino, Norman Wolmark
Barriers to physical activity and healthy eating in young breast cancer survivors: modifiable risk factors and associations with body mass index
Emily E. Ventura, Patricia A. Ganz, Julienne E. Bower, Liana Abascal, Laura Petersen, Annette L. Stanton, Catherine M. Crespi
Aromatase inhibitor therapy and hair loss among breast cancer survivors
Lisa Gallicchio, Carla Calhoun, Kathy J. Helzlsouer
Is there a role for routine screening MRI in women with LCIS?
Tari A. King, Shirin Muhsen, Sujata Patil, Starr Koslow, Sabine Oskar, Anna Park, Mary Morrogh, Rita A. Sakr, Monica Morrow
Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93
Olivia Pagani, Shari Gelber, Marco Colleoni, Karen N. Price, Edda Simoncini
Closing an on-going clinical trial: when is it betrayal of participants?
Cynthia Chauhan, Mary Lou Smith
Margin negative, breast conserving resection: adequate for benign phyllodes tumors, but inadequate therapy for borderline and malignant phyllodes tumors
Richard J. Barth Jr.